Related Experiment Video

Updated: May 13, 2026

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies
09:29

Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies

Published on: September 30, 2016

Individualized therapy for metastatic colorectal cancer

A Silvestri1, E Pin, A Huijbers

  • 1Division of Experimental Oncology 2, CRO-IRCCS, National Cancer Institute, Aviano, Italy.

Journal of Internal Medicine
|March 27, 2013
PubMed

Insights

Predictive biomarkers are crucial for optimizing treatment efficacy and minimizing toxicity in metastatic colorectal cancer (CRC) patients. Genomic and proteomic advancements are paving the way for personalized medicine in CRC therapy.

Area of Science:

  • Oncology
  • Genomics
  • Proteomics

Background:

  • Systemic therapeutic efficacy is key for patient outcomes in metastatic colorectal cancer (CRC).
  • There's a critical need for predictive biomarkers to enhance treatment effectiveness and reduce toxicity in CRC patients.
  • Personalized medicine approaches are gaining traction in CRC treatment.

Purpose of the Study:

  • To review the latest advancements in genomic and proteomic predictive biomarkers for individualized therapy in metastatic CRC.
  • To highlight the potential of personalized medicine in optimizing CRC treatment strategies.

Main Methods:

  • Literature review focusing on recent progress in genomic and proteomic research.
  • Analysis of predictive biomarkers relevant to individualized therapy in metastatic CRC.

Main Results:

  • Significant progress has been made in identifying genomic and proteomic biomarkers.
  • These biomarkers show promise for tailoring treatments to individual metastatic CRC patients.
  • The integration of targeted drugs and molecular profiling is advancing personalized CRC therapy.

Conclusions:

  • Genomic and proteomic biomarkers are essential for personalized medicine in metastatic CRC.
  • Further research in these fields will refine individualized treatment strategies and improve patient outcomes.
  • Optimizing therapeutic efficacy and minimizing toxicity are achievable through biomarker-driven approaches.

More Related Videos

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer06:19

Isolation of Circulating Tumor Cells in an Orthotopic Mouse Model of Colorectal Cancer

Published on: July 18, 2017

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy08:54

Treatment of Liver Metastases Using an Internal Target Volume Method for Stereotactic Body Radiotherapy

Published on: May 8, 2018

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...